Cited by 126Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and TreatmentClinical Laboratory Practices and Quality Control

The Use and Limitations of a Chemiluminescent Thyrotropin Assay as a Single Thyroid Function Test in an Out-Patient Endocrine Clinic*

ROSS, DOUGLAS S., DANIELS, GILBERT H., GOUVEIA, DIANE·1990·The Journal of Clinical Endocrinology & Metabolism

Abstract

A chemiluminescent TSH assay (detection limit, less than 0.01 mU/L) allows for accurate measurement of subnormal TSH concentrations. We retrospectively analyzed serum TSH and the free T4 (fT4) index of 460 consecutive endocrine clinic visits to determine the usefulness of TSH measurements alone in the assessment of thyroid function. Additionally, case histories were presented nonconsecutively to one of us (TSH alone or TSH with fT4) to determine if knowledge of the fT4 level would alter management. Of hypothyroid patients on replacement therapy (n = 127), 60% had concordant fT4 and TSH, 14% had subnormal TSH with normal fT4, 18% had high TSH with normal fT4, and 4% normal TSH with high fT4; only 4% were managed differently when the fT4 level was known in addition to TSH. Of the patients receiving suppressive therapy with TSH levels above 0.05 mU/L (n = 81), only 4% were managed differently when fT4 was known; 4% had high fT4. With TSH levels below 0.05 mU/L (n = 64), knowledge of fT4 was felt to be necessary for management in all cases; 53% had high fT4. Twenty-three of 46 (50%) patients being treated for hyperthyroidism had discordant TSH and fT4, including 7 patients with low TSH and low fT4. Two of 21 (10%) patients screened with pituitary/hypothalamic disease had discordant TSH and fT4, and 4 of 9 (44%) patients treated with L-T4 for secondary hypothyroidism had subnormal TSH. Knowledge of fT4 was felt to be necessary in all these cases. We conclude that TSH alone is sufficient for screening and monitoring L-T4 replacement or suppression therapy if TSH levels are above 0.05 mU/L. These patients account for the majority of visits to our endocrine clinic. TSH alone is misleading in pituitary disease and during the treatment of hyperthyroidism. fT4 is needed if TSH levels are less than 0.05 mU/L to assess the degree of hyperthyroidism.

Integrity signals

Registry

Crossref · 10.1210/jcem-71-3-764

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Non-optimal thyroxine therapy, as evidenced by TSH levels above or below the reference range, is common in hypothyroid patients.

    “Even though its prevalence has not been precisely documented, non-optimal thyroxine therapy, as evidenced by TSH levels above (or below) the reference range, is common (Table 2)”
  • Five to 24 percent of all patients taking L-T4 develop iatrogenic thyrotoxicosis, a proportion that is even higher in the elderly (up to 41%).

    “Five to 24 percent of all patients taking L-T4 develop iatrogenic thyrotoxicosis (9, 11, 78, 81–83), a proportion that is even higher in the elderly [up to 41% (79)].”

The citation lists haven’t been fetched yet

References 18 · Cited by 126

Authors
ROSS, D. S., DANIELS, G. H., & GOUVEIA, D.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1990-09
Volume
71
Issue
3
Pages
764-769
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2069654197
Cited by
126
References
18
Citations by year
2025: 1 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 1 · 2013: 5 · 2012: 1
FWCI
2.52
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5k08dk001415-05)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-01415)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
Keywords
thyroid-stimulating hormone, free thyroxine, thyroid function tests, hypothyroidism, hyperthyroidism, TSH receptor antibodies, levothyroxine replacement therapy, TSH suppression therapy, pituitary disorders, thyroid screening, diagnostic agreement, clinical decision-making, low TSH
MeSH terms
Aged, Ambulatory Care Facilities, False Negative Reactions, Female, Humans, Immunoassay, Luminescent Measurements, Reagent Kits, Diagnostic, Thyroid Diseases, Thyroid Function Tests, Thyrotropin, Thyroxine, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review